Back to today’s briefing

Story perspectives

MIT Breakthrough Drug Normalizes Protein in Fragile X Syndrome

3/5/2025

50 11

Summary

Story summary

MIT scientists have made a groundbreaking advancement in treating fragile X syndrome, a major genetic contributor to autism. Their innovative approach targets the NMDA receptor's 2B subunit, successfully reducing excessive protein production in mouse models. The experimental drug Glyx-13 not only normalized protein levels but also significantly decreased seizures, paving the way for potential therapies for those affected by fragile X.

1 of 1

Story summary

MIT scientists have made a groundbreaking advancement in treating fragile X syndrome, a major genetic contributor to autism. Their innovative approach targets the NMDA receptor's 2B subunit, successfully reducing excessive protein production in mouse models. The experimental drug Glyx-13 not only normalized protein levels but also significantly decreased seizures, paving the way for potential therapies for those affected by fragile X.